Brazilian Antirheumatic Drugs market was valued at US$4,495.339 million in 2019. The growing aging population in Brazil is the major factor that is driving the demand for antirheumatic drugs in the country. Recovery of the Brazilian economy can be witnessed by increasing purchasing power and corresponding shift towards a fast-food diet, leading to rising cases of obesity and diabetes in the country. According to the World Health Organization (WHO), the prevalence of diabetes has increased steadily since 1980, with 7.4% of males and 8.8% of females suffering from diabetes in Brazil. Moreover, half of the Brazilian population is overweight while 20% are obese. As such, the cases of arthritis is increasing in the country, thereby driving the market growth of antirheumatic drugs market.
The rise in the sales of generic drugs in Brazil owing to the Generic Medicines Policy passed in 1999 by the Brazilian government is another driver that is boosting the growth of the country’s antirheumatic drugs market. Since many Brazilians still cannot afford medications, the development of low-cost generic drugs are helping to expand access to more underserved populations. Furthermore, the Brazilian Institute of Geography and Statistics estimated that the senior population of Brazil will surpass its young population over the next two decades which further drives the need for a variety of affordable medicines for age-related diseases in order to maintain the overall healthcare expenditure.
The Brazilian Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, Brazil Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).